The effectiveness of telemonitoring and integrated personalized diabetes management in people with insulin‐treated type 2 diabetes mellitus
Primary result · HbA1c change from baselineResult — go to the resultMean difference −0.65 % 95% CI −0.99 to −0.30Authors' conclusion
Telemonitoring can support the iPDM care model in individuals with insulin-treated type 2 diabetes. It improves the efficiency of diabetes care, enhances glycaemic control at 12 weeks, and sustains glycaemic control at 24 weeks.
Study context
- Population
- Insulin-treated T2D patients aged 18–65 years with HbA1c 7.5%-10.5%
- Participants
- 151 patients
- Comparison
- Telemonitoring-based integrated personalized diabetes management (iPDM) vs self-monitoring and insulin adjustment
- Primary endpoint
- Difference in HbA1c change from baseline between groups
- Follow-up
- 24 weeks
Methodological detailssingle-centre, open-label, prospective
- Single-centre
- Open-label
- Prospective
Primary result
HbA1c change from baseline
Mean difference
−0.65 %
95% CI −0.99 to −0.30
P < 0.001
Change by group
tele-iPDM
−1.14
CI −1.38–-0.89 · %
Control
- 0.49
CI −0.73–-0.25 · %
tele-iPDMvs Control
mean difference −0.65 % (95% CI −0.99 to −0.30); P < 0.001
As reported in the abstract
Secondary outcomes
%
| Outcome | tele-iPDM | Control | Mean difference (%) (95% CI) | P value | |
|---|---|---|---|---|---|
| HbA1c change from baseline · 12 weeks | −1.2 (CI −1.42–-0.98) | −0.57 (CI −0.79–-0.36) | −0.63 (−0.94 to −0.32) | P < 0.001 | |
| −1−0.500.5Difference, % (linear scale) |
Body weight and body mass index (BMI)
- No significant differences in body weight or BMI between groups
Safety
- No significant difference in hypoglycaemic events between groups
Original publication
The effectiveness of telemonitoring and integrated personalized diabetes management in people with insulin‐treated type 2 diabetes mellitus. Diabetes Obes Metab. Published 19 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →